Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
32 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CI-1012
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serologic evidence of infection with HIV-1.
* CD4+ cell count \>= 200 cells/mm3.
* HIV-1 RNA \>= 10,000 copies/ml.
Exclusion Criteria
Patients with the following conditions are excluded:
Viral, fungal, or bacterial infection requiring therapy other than topical medications.
Concurrent Medication:
Excluded:
* Prophylactic systematic antibacterial, antifungal or antiviral agents.
* Antiretroviral therapy. NOTE:
* Patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication.
Prior Medication:
Excluded:
* Experimental therapy for \>= 4 weeks prior to initiation of study medication.
* Antiretroviral treatment for 3 weeks prior to initiation of study medication.
* Systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parke-Davis
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ViRx Inc
Palm Springs, California, United States
ViRx Inc
San Francisco, California, United States
Central Florida Research Initiative
Maitland, Florida, United States
Natl Institutes of Health
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1012-005
Identifier Type: -
Identifier Source: secondary_id
278A
Identifier Type: -
Identifier Source: org_study_id